PL1653930T3 - Sposoby stabilizacji atorwastatyny - Google Patents

Sposoby stabilizacji atorwastatyny

Info

Publication number
PL1653930T3
PL1653930T3 PL04738465T PL04738465T PL1653930T3 PL 1653930 T3 PL1653930 T3 PL 1653930T3 PL 04738465 T PL04738465 T PL 04738465T PL 04738465 T PL04738465 T PL 04738465T PL 1653930 T3 PL1653930 T3 PL 1653930T3
Authority
PL
Poland
Prior art keywords
kpa
stabilization
preferably less
partial pressure
gaseous mixture
Prior art date
Application number
PL04738465T
Other languages
English (en)
Inventor
Pavel Sebek
Alena Prokopova
Eduard Svoboda
Stanislav Radl
Jan Stach
Martin Svoboda
Andrej Kovacik
Adrian Danko
Roman Petro
Miroslav Strizinec
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34117186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1653930(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ20032135A external-priority patent/CZ295027B6/cs
Priority claimed from CZ20040857A external-priority patent/CZ2004857A3/cs
Application filed by Zentiva Ks filed Critical Zentiva Ks
Publication of PL1653930T3 publication Critical patent/PL1653930T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PL04738465T 2003-08-05 2004-08-05 Sposoby stabilizacji atorwastatyny PL1653930T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CZ20032135A CZ295027B6 (cs) 2003-08-05 2003-08-05 Způsob stabilizace farmaceutické kompozice
CZ20040857A CZ2004857A3 (cs) 2004-08-03 2004-08-03 Zpusob stabilizace farmaceutické úcinné tuhé látky atorvastatinu
EP04738465A EP1653930B1 (en) 2003-08-05 2004-08-05 Methods for the stabilization of atorvastatin
PCT/CZ2004/000045 WO2005011638A2 (en) 2003-08-05 2004-08-05 Methods for the stabilization of atorvastatin

Publications (1)

Publication Number Publication Date
PL1653930T3 true PL1653930T3 (pl) 2008-06-30

Family

ID=34117186

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04738465T PL1653930T3 (pl) 2003-08-05 2004-08-05 Sposoby stabilizacji atorwastatyny
PL379195A PL379195A1 (pl) 2003-08-05 2004-08-05 Sposoby stabilizacji atorwastatyny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL379195A PL379195A1 (pl) 2003-08-05 2004-08-05 Sposoby stabilizacji atorwastatyny

Country Status (13)

Country Link
US (1) US20080171784A1 (pl)
EP (1) EP1653930B1 (pl)
AT (1) ATE381322T1 (pl)
CA (1) CA2535225A1 (pl)
DE (1) DE602004010817T2 (pl)
EA (1) EA007345B1 (pl)
ES (1) ES2298763T3 (pl)
HR (1) HRP20060089B1 (pl)
PL (2) PL1653930T3 (pl)
PT (1) PT1653930E (pl)
RS (1) RS20060081A (pl)
SK (1) SK50462005A3 (pl)
WO (1) WO2005011638A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI321132B (en) * 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
CZ300047B6 (cs) * 2007-03-02 2009-01-21 Zentiva, A. S. Farmaceutická kompozice s obsahem úcinné látky atorvastatinu
EP2127628A1 (en) 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
TR200806300A2 (tr) * 2008-08-22 2010-03-22 B�Lg�� Mahmut Çözünürlük artırıcı farmasötlk formulasyon
WO2011077843A1 (ja) 2009-12-25 2011-06-30 沢井製薬株式会社 アトルバスタチン含有被覆製剤
EP2787987B1 (de) * 2011-12-08 2016-06-01 Hexal AG Neue pharmazeutische statin-zusammensetzung
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
EP3143988A1 (en) 2013-03-14 2017-03-22 Fresenius Kabi Deutschland GmbH Injectable morphine formulations
CN204798475U (zh) 2013-03-14 2015-11-25 贝克顿狄金森法国公司 用于可注射氧敏感药物和可注射吗啡的医药包装系统
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
EP3272336A1 (de) 2016-07-19 2018-01-24 Stada Arzneimittel Ag Atorvastatin-zusammensetzung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
WO2001093859A1 (en) * 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
EP1241110A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
OA12777A (en) * 2002-02-14 2006-07-06 Ranbaxy Lab Ltd Formulations of atorvastatin stabilized with alkali metal additions.
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Also Published As

Publication number Publication date
DE602004010817D1 (de) 2008-01-31
EA200500819A1 (ru) 2006-02-24
ES2298763T3 (es) 2008-05-16
SK50462005A3 (sk) 2005-09-08
WO2005011638A3 (en) 2005-10-20
HRP20060089A2 (en) 2006-05-31
CA2535225A1 (en) 2005-02-10
US20080171784A1 (en) 2008-07-17
DE602004010817T2 (de) 2008-12-11
RS20060081A (en) 2008-06-05
EA007345B1 (ru) 2006-08-25
PL379195A1 (pl) 2006-07-24
EP1653930A2 (en) 2006-05-10
PT1653930E (pt) 2008-03-12
HRP20060089B1 (en) 2008-05-31
EP1653930B1 (en) 2007-12-19
ATE381322T1 (de) 2008-01-15
WO2005011638A2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
HRP20060089B1 (en) Method for the stabilization of atorvastatin
CA2489956A1 (en) Generation of elevated pressure gas mixtures by adsorption and stripping
MXPA03000001A (es) Nuevo metodo para obtener formulaciones acuosas con principios activos susceptibles a oxidacion y las soluciones acuosas obtenidas de este modo.
IN2014DN07569A (pl)
UA85715C2 (ru) упакованная изоляционная продукция и способ упаковки изоляционной продукции
AR022866A1 (es) Conjunto que comprende una bebida envasada lista para beber y dicha bebida envasada lista para beber.
WO2005122774A3 (en) Packaging of meat prodcuts with modified atmospheres and/or enhancers
GR3025966T3 (en) Method for manufacturing and storing stable bicarbonate solutions.
RS20050273A (en) Stabilized pharmaceutical preparation comprising an amorphous active substance
WO2009041049A1 (ja) 殺菌方法および装置
EP1243524A3 (en) Pharmaceutical kit for oxygen-sensitive drugs
AU2002365135A1 (en) Integrated oxygen generation and carbon dioxide absorption method, apparatus and systems
AU2003301519A1 (en) Method and apparatus for filling portable high pressure cylinders with respiratory oxygen
NZ507635A (en) Modifying the atmosphere in a refrigerated container using an apparatus to withdraw gaseous by-products and filter the by-products prior to its return
DE602005026905D1 (de) Produktabgabesystem und dessen herstellungsverfahren
AU2003285567A1 (en) Apparatus and process for carbon dioxide absorption
MY141989A (en) Drug delivery assembly
WO2003037388A3 (en) System and method for de-contaminating and/or sanitizing
WO2007044835A3 (en) Apparatus, system, and method for storage of mushrooms
WO2002026059A3 (en) Method for preserving food products using biological modified atmosphere packaging
WO2008079947A3 (en) Gaseous sterilization of impermeable containers through use of porous material
EP1544169A4 (en) ACTIVE OXYGEN CONTAINING INORGANIC COMPOUND AND MANUFACTURING METHOD DAF R
CA2489738A1 (en) Modified atmosphere packaging for seafood
AU2002214090A1 (en) Method and installation for packaging a liquid product in a package
AU2004100866A4 (en) Wine Extenda